Using exenatide twice daily or insulin in clinical practice: Results from choice

Diabetes Therapy

Volumn 4, Issue 2, 2013, Pages 285-308

  Mathieu, Chantal ^a   Ostenson, Claes Göran ^b   Matthaei, Stephan ^c   Reaney, Matthew ^d   Krarup, Thure ^e   Guerci, Bruno ^f   Kiljński, Jacek ^g   Salaun Martin, Carole ^h   Sapin, Hélène ^h   Theodorakis, Michael ⁱ  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Diabetes Zentrum Quakenbruck   (Germany)

^d ELI LILLY AND COMPANY   (United States)

^e BISPEBJERG HOSPITAL   (Denmark)

^f CHU NANCY BRABOIS   (France)

^g Eli Lilly Polska Sp z oo   (Poland)

^h Eli Lilly   (France)

ⁱ UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Diabetes mellitus; Exenatide; Injectable therapy; Insulin; Type 2

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; LONG ACTING INSULIN; MEGLITINIDE; METFORMIN; SHORT ACTING INSULIN; SULFONYLUREA;

ADULT; ARTICLE; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; WEIGHT REDUCTION;

EID: 84892887494     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-013-0037-8     Document Type: Article

References (34)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577-96.
2. Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007;29:2333-48.
3. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143:559-69.
4. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007;50:259-67.
5. Dreyer NA, Tunis SR, Berger M, Ollendorf D, Mattox P, Gliklich R. Why observational studies should be among the tools used in comparative effectiveness research. Health Aff (Millwood). 2010;10:1818-25.
6. Ware JH, Hamel MB. Pragmatic trials-guides to better patient care? N Engl J Med. 2011;364:1865-7.
7. Ligthelm RJ, Borzì V, Gumprecht J, Kawamori R, Wenying Y, Valensi P. Importance of observational studies in clinical practice. Clin Ther. 2007;29 Spec No:1284-92.
8. Mann CJ. Observational research methods. Research design II: cohort, cross sectional, and case-control studies. Emerg Med J. 2003;20:54-60.
9. Matthaei S, Reaney M, Mathieu C, et al. Patients with type 2 diabetes initiating exenatide BID or insulin in clinical practice: CHOICE study. Diabetes Ther. 2012;3:6.
10. Jones S, Benroubi M, Castell C, et al. Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study. Curr Med Res Opin. 2009;25:691-700.
11. Yue LQ. Statistical and regulatory issues with the application of propensity score analysis to nonrandomized medical device clinical studies. J Biopharm Stat. 2007;17:1-13.
12. Zinman B, Schmidt WE, Moses A, et al. Achieving a clinically relevant composite outcome of an HbA1c of >7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab. 2012;14:77-82.
13. Benroubi M, Schmitt H, Cleall SP, et al., TREAT Study Investigators. Costs and clinical outcomes after 24 months of insulin therapy in patients with type 2 diabetes: results from the TREAT study. Poster presented at the 47th European Association for the Study of Diabetes (EASD) Annual Meeting, Lisbon, Portugal, 12-16 September 2011.
14. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12.
15. Gallwitz B, Guzman J, Dotta F, et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet. 2012;379:2270-8.
16. Holman RR, Thorne KI, Farmer AJ, 4-T Study Group, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716-30.
17. Holman RR, Farmer AJ, Davies MJ, 4-T Study Group, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736-47.
18. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-100.
19. Buse JB, Henry RR, Han J, Exenatide-113 Clinical Study Group, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-35.
20. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-91.
21. Bergenstal RM, Garrison LP, Miller LA, et al. Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting. Curr Med Res Opin. 2011;27:2335-42.
22. Bergenstal RM, Garrison LP Jr, Wintle M, et al. Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting. Curr Med Res Opin. 2011;27:531-40.
23. Brixner DI, McAdam-Marx C, Ye X, et al. Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes Obes Metab. 2009;11:1122-30.
24. Ryder REJ, Thong KY, Cull ML, et al., ABCD Nationwide Exenatide Audit Contributors. The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Pract Diab Int. 2010;27:352-7.
25. Exenatide injection [package insert]. San Diego: Amylin Pharmaceuticals, Inc; 2011.
26. Liebl A, Jones S, Goday A, et al. Clinical outcomes after insulin initiation in patients with type 2 diabetes: 24-month results from INSTIGATE. Diabetes Ther. 2012;3:9.
27. Bennett WL, Balfe LM, Faysal JM. AHRQ's comparative effectiveness research on oral medications for type 2 diabetes: a summary of the key findings. J Manag Care Pharm. 2012;18(1 Suppl. A):1-22.
28. Russell-Jones D, Vaag A, Schmitz O, Liraglutide effect and action in Diabetes 5 (LEAD-5) met + SU Study Group, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia. 2009;52:2046-55.
29. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375:2234-43.
30. Waugh N, Cummins E, Royle P, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2010;14:1-248.
31. Gale EA. Post-marketing studies of new insulins: sales or science? BMJ. 2012;344:e3974.
32. Yudkin JS. Post-marketing observational trials and catastrophic health expenditure. BMJ. 2012;344: e3987.
33. Byetta approved for use with basal insulin in Europe (press release). San Diego, CA: Amylin Pharmaceuticals, Inc. c2012 (updated March 23, 2012; cited June 13, 2012). https://investor.lilly.com/releasedetail2.cfm?ReleaseID=659089. Accessed 12 Dec 2012.
34. Ryder RJ, Thong K, ABCD Nationwide Exenatide and Liraglutide Audit Contributors. ABCD Nationwide Exenatide and Liraglutide Audits. Oral presentation at the diabetes UK annual professional conference, London, 30 March-1 April 2011